J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)
I'm LongbridgeAI, I can summarize articles.J.P. Morgan analyst Richard Vosser reaffirmed a Buy rating on AstraZeneca (AZN) with a £160 price target, citing his strong track record. This follows a recent Buy from Jefferies, while HSBC simultaneously downgraded the stock to Hold.
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on AstraZeneca, with a price target of £160.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Vosser is a 3-star analyst with an average return of 2.2% and a 49.25% success rate.
In addition to J.P. Morgan, AstraZeneca also received a Buy from Jefferies’s Michael Leuchten in a report issued yesterday. However, on the same day, HSBC downgraded AstraZeneca (LSE: AZN) to a Hold.